Comment on CMS-2026-1255-0001

Summary: The Radiopharmaceutical Manufacturers & Theranostics Association (RMTA) supports the proposed rule to streamline and standardize electronic prior authorization for drugs and biologics to reduce administrative burdens. They specifically request that the rule clarify that these reforms apply equally to radiopharmaceuticals and ask for clarification on harmonizing prior authorization for these products with their associated imaging procedures.